The NYT continues its excellent coverage of abuses in the prescription drug industry. It pointed out that several doctors questioned whether a new study by GlaxoSmithKline, that was supposed to demonstrate the safety of one its diabetes drugs, in fact showed that the study was safe.
It's great that the NYT has devoted so much of its resources to uncovering efforts by the drug industry to mislead the public about the safety and effectiveness of its drugs. However, it would be even better if it devoted attention to the nature of the patent system that provides such enormous incentives for such abuses. There are alternative methods for financing prescription drug development. Until we adopt an alternative model, we can expect to see many more pieces exposing the abuses of the current one.
There's too much at stake this November for us to quit. As we navigate another presidential election year, thoughtful independent journalism is more important than ever. We're committed to bringing you the latest news on what's really happening across the country this election season, shining a light on the stories corporate media overlooks and keeping the public informed about how power really works in America.
Quality reporting doesn't come for free, and we don't have corporate backers to rely on to fund our work. Everything we do is thanks to our incredible community of readers, who chip in a few dollars at a time to make what we do possible. This month, we're trying to raise $50,000 to help fuel our election coverage, and we've fallen behind on reaching our goal. Any amount you give today will bring us closer to making our reporting possible—and a generous donor has agreed to match all online donations, so your impact will be doubled.
